PMID- 35772235
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220816
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 219
DP  - 2022 Sep 20
TI  - High-resolution mass spectrometry assay for quantifying ceramides and 
      dihydroceramides in the cerebrospinal fluid from patients who experienced 
      intracranial infection after craniotomy.
PG  - 114907
LID - S0731-7085(22)00328-4 [pii]
LID - 10.1016/j.jpba.2022.114907 [doi]
AB  - Ceramides (CERs) and dihydroceramides (dhCERs) are biologically active lipids 
      involved in cell proliferation, differentiation, and apoptosis, as well as 
      associated with infectious diseases. The concentration of CERs and dhCERs in the 
      cerebrospinal fluid (CSF) could potentially allow the distinction of patients 
      with intracranial infection (ICI) after craniotomy from controls, but the 
      quantification is limited by their ultralow concentrations. Therefore, a novel 
      high performance liquid chromatography-triple-quadrupole/time-of-flight mass 
      spectrometry (HPLC-QTOF-MS) with Sequential Window Acquisition of All Theoretical 
      Fragment Ion Spectra (SWATH) was applied to measure CERs and dhCERs in CSF, since 
      it possesses a higher sensitivity (LLOQ = 0.1 pmol/mL) than the multiple reaction 
      monitoring (MRM) acquisition carried on triple quadrupole (QqQ) MS. This method 
      was validated and applied to CSF samples from patients who experienced 
      postoperative ICI (63 patients) and controls who did not experience it after 
      surgery (62 patients). This assay was linear over the measuring range 0.1-100 
      pmol/mL for these CER and dhCER species with good accuracy and precision. 
      Elevated CERs and dhCERs were observed in CSF from patients who experienced 
      postoperative ICI. CER 16:0 was found with a clinical sensitivity of 93.65 % and 
      specificity of 87.1 % in distinguishing the 63 patients with ICI from the 62 
      controls. Therefore, this method could be applied in the detection of CERs and 
      dhCERs in CSF, which were correlated with the presence of ICI.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Shi, Jiawei
AU  - Shi J
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Wang, Tingting
AU  - Wang T
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Guo, Haiyang
AU  - Guo H
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Li, Chen
AU  - Li C
AD  - Department of Neurosurgery, The First Hospital of Jilin University, Jilin 130021, 
      China.
FAU - Li, Li
AU  - Li L
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Jin, Yuting
AU  - Jin Y
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Chen, Haizhen
AU  - Chen H
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Clinical Laboratory, The First Hospital of Jilin University, Jilin 
      130021, China; Department of Neurosurgery, The First Hospital of Jilin 
      University, Jilin 130021, China. Electronic address: huangj@jlu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220623
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Ceramides)
RN  - 0 (dihydroceramide)
SB  - IM
MH  - *Ceramides
MH  - Chromatography, High Pressure Liquid
MH  - *Craniotomy/adverse effects
MH  - Humans
MH  - Mass Spectrometry
OTO - NOTNLM
OT  - Ceramide
OT  - Dihydroceramide
OT  - HRMS
OT  - Intracranial infection after craniotomy
OT  - SWATH
EDAT- 2022/07/01 06:00
MHDA- 2022/08/17 06:00
CRDT- 2022/06/30 18:16
PHST- 2022/01/05 00:00 [received]
PHST- 2022/06/13 00:00 [revised]
PHST- 2022/06/20 00:00 [accepted]
PHST- 2022/07/01 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/06/30 18:16 [entrez]
AID - S0731-7085(22)00328-4 [pii]
AID - 10.1016/j.jpba.2022.114907 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2022 Sep 20;219:114907. doi: 10.1016/j.jpba.2022.114907. 
      Epub 2022 Jun 23.